ImmunityBio (IBRX) Moves to Buy: Rationale Behind the Upgrade

Core Viewpoint - ImmunityBio (IBRX) has received an upgrade to a Zacks Rank 2 (Buy), indicating a positive shift in earnings estimates which is a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Price Impact - The Zacks rating system reflects changes in earnings estimates, which are strongly correlated with stock price movements, particularly due to institutional investors adjusting their valuations based on these estimates [4][6]. - For the fiscal year ending December 2025, ImmunityBio is expected to earn -$0.43 per share, representing a 41.1% change from the previous year's reported number [8]. Analyst Sentiment and Market Position - Analysts have raised their earnings estimates for ImmunityBio, with the Zacks Consensus Estimate increasing by 46.6% over the past three months [8]. - The upgrade to Zacks Rank 2 places ImmunityBio in the top 20% of Zacks-covered stocks, suggesting potential for market-beating returns in the near term [10].